Close Menu

NEW YORK (360Dx) – French biopharmaceuticals and diagnostics firm Genfit today announced the pricing of a global offering of 6.65 million ordinary shares and anticipates gross proceeds of about $135.1 million before deducting underwriting commissions and expenses.

The global offering consists of 6.15 million ordinary shares in the form of American Depositary Shares at an offering price of $20.32 per ADS. The company initiated a concurrent private placement of 500,000 ordinary shares in countries outside the US at the corresponding offering price of €18 ($20.25) per ordinary share.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.